Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma

  • STATUS
    Recruiting
  • End date
    Feb 1, 2023
  • participants needed
    50
  • sponsor
    University of Rochester
Updated on 29 January 2021

Summary

To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

Details
Condition Advanced Renal Cell Carcinoma
Treatment Carevive software
Clinical Study IdentifierNCT03229083
SponsorUniversity of Rochester
Last Modified on29 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Advanced Renal Cell Carcinoma?
Do you have any of these conditions: Do you have Advanced Renal Cell Carcinoma??
Do you have any of these conditions: Do you have Advanced Renal Cell Carcinoma??
Do you have any of these conditions: Do you have Advanced Renal Cell Carcinoma??
Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease
Greater than 18 years of age
A participating Wilmot Cancer Center oncologist has determined that candidate should be started on either oral targeted therapy or immunotherapy for treatment of their advanced RCC; this can be for first-line or any subsequent line therapy
Able to provide written informed consent
Proficient in the English language and self-reports as literate
Must have an active email address or access to a smart device on which text messages can be received

Exclusion Criteria

Women cannot be breast-feeding
Does not have regular access to the internet
Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for routine visits with their primary oncologist
Subjects who were on the study previously will not be allowed to re-enroll in the event of a treatment change
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note